Cell Line Derived Multi-Gene Predictor of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer: A Validation Study on US Oncology 02-103 Clinical Trial

by Shen Kui, Qi Yuan, Song Nan, Tian Chunqiao, Rice Shara D, Gabrin Michael J, Brower Stacey L, Symmans William Fraser, O’Shaughnessy Joyce A, Holmes Frankie A, Asmar Lina, Pusztai Lajos
Published 2012-11-01

The influences of cytotoxic drugs and L1210 suspension culture density on de novo purine synthesis

by O'Shaughnessy, Joyce Ann
Published 1982

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.

by Cortés, Javier, Rugo, Hope S, Twelves, Chris, Awada, Ahmad, Perez, Edith A, Im, Seock-Ah, Zhao, Carol, Hoch, Ute, Tomkinson, Denise, Buchanan, James, Tagliaferri, Mary, Hannah, Alison, O'Shaughnessy, Joyce
Published 2016

Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.

by O'Shaughnessy, Joyce A, Kelloff, Gary J, Gordon, Gary B, Dannenberg, Andrew J, Hong, Waun Ki, Fabian, Carol J, Sigman, Caroline C, Bertagnolli, Monica M, Stratton, Steven P, Lam, Stephen, Nelson, William G, Meyskens, Frank L, Alberts, David S, Follen, Michele, Rustgi, Anil K, Papadimitrakopoulou, Vali, Scardino, Peter T, Gazdar, Adi F, Wattenberg, Lee W, Sporn, Michael B, Sakr, Wael A, Lippman, Scott M, Von Hoff, Daniel D
Published 2002

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial

by Cortes, Javier, Rugo, Hope S., Twelves, Chris, Awada, Ahmad, Perez, Edith A., Im, Seock-Ah, Zhao, Carol, Hoch, Ute, Tomkinson, Denise, Buchanan, James, Tagliaferri, Mary, Hannah, Alison, O'Shaughnessy, Joyce]
Published 2022

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.

by Rugo, Hope S, Dieras, Veronique, Cortes, Javier, Patt, Debra, Wildiers, Hans, O'Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A, Carter, Gebra Cuyun, Sheffield, Kristin M, Li, Li, Andre, Valerie AM, Li, Xiaohong I, Frenzel, Martin, Huang, Yu-Jing, Dickler, Maura N, Tolaney, Sara M
Published 2020

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

by Cortes, Javier, Rugo, Hope S., Awada, Ahmad, Twelves, Chris, Perez, Edith A., Im, Seock-Ah, Gomez-Pardo, Patricia, Schwartzberg, Lee S., Dieras, Veronique, Yardley, Denise A., Potter, David A., Mailliez, Audrey, Moreno-Aspitia, Alvaro, Ahn, Jin-Seok, Zhao, Carol, Hoch, Ute, Tagliaferri, Mary, Hannah, Alison L., O'Shaughnessy, Joyce]
Published 2022

Change in topoisomerase 1–positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol

by Rugo, Hope S., Cortes, Javier, Awada, Ahmad, O'Shaughnessy, Joyce, Twelves, Chris, Im, Seock-Ah, Hannah, Alison, Lu, Lin, Sy, Sherwin, Caygill, Katie, Zajchowski, Deborah A., Davis, Darren W., Tagliaferri, Mary, Hoch, Ute, Perez, Edith A.]
Published 2022

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

by Tripathy, Debu, Rugo, Hope S, Kaufman, Peter A, Swain, Sandra, O'Shaughnessy, Joyce, Jahanzeb, Mohammad, Mason, Ginny, Beattie, Mary, Yoo, Bongin, Lai, Catherine, Masaquel, Anthony, Hurvitz, Sara
Published 2014

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised...

by Miles, David, Cameron, David, Bondarenko, Igor, Manzyuk, Lyudmila, Alcedo, Juan Carlos, Lopez, Roberto Ivan, Im, Seock-Ah, Canon, Jean-Luc, Shparyk, Yaroslav, Yardley, Denise A., Masuda, Norikazu, Ro, Jungsil, Denduluri, Neelima, Hubeaux, Stanislas, Quah, Cheng, Bais, Carlos, O'Shaughnessy, Joyce]
Published 2022

De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.

by Tripathy, Debu, Brufsky, Adam, Cobleigh, Melody, Jahanzeb, Mohammad, Kaufman, Peter A, Mason, Ginny, O'Shaughnessy, Joyce, Rugo, Hope S, Swain, Sandra M, Yardley, Denise A, Chu, Laura, Li, Haocheng, Antao, Vincent, Hurvitz, Sara A
Published 2019

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from t...

by Twelves, Chris, Cortes, Javier, O'Shaughnessy, Joyce, Awada, Ahmad, Perez, Edith A., Im, Seock-Ah, Gomez-Pardo, Patricia, Schwartzberg, Lee S., Dieras, Veronique, Yardley, Denise A., Potter, David A., Mailliez, Audrey, Moreno-Aspitia, Alvaro, Ahn, Jin-Seok, Zhao, Carol, Hoch, Ute, Tagliaferri, Mary, Hannah, Alison L., Rugo, Hope S.]
Published 2022

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEAC...

by Perez, Edith A., Awada, Ahmad, O'Shaughnessy, Joyce, Rugo, Hope S., Twelves, Chris, Im, Seock-Ah, Gomez-Pardo, Patricia, Schwartzberg, Lee S., Dieras, Veronique, Yardley, Denise A., Potter, David A., Mailliez, Audrey, Moreno-Aspitia, Alvaro, Ahn, Jin-Seok, Zhao, Carol, Hoch, Ute, Tagliaferri, Mary, Hannah, Alison L., Cortes, Javier]
Published 2022

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

by Gelmon, Karen A., Fasching, Peter A., Couch, Fergus J., Balmaña, Judith, Delaloge, Suzette, Labidi-Galy, Intidhar, Bennett, James, McCutcheon, Susan, Walker, Graham, O'Shaughnessy, Joyce, Collaborating Investigator, Timcheva, Constanta, Tomova, Antoaneta, Eisen, Andrea, Lemieux, Julie, Bazan, Fernando, Bourgeois, Hugues, Chakiba, Camille, Chehimi, Mohamad, Dalenc, Florence, De La Motte Rouge, Thibault, Frenel, Jean-Sébastien, Gonçalves, Anthony, Hardy-Bessard, Anne Claire, Lamy, Regine, Levy, Christelle, Lortholary, Alain, Mailliez, Audrey, Medioni, Jacques, Patsouris, Anne, Spaeth, Dominique, Teixeira, Luis, Tennevet, Isabelle, Villanueva, Cristian, You, Benoit, Ettl, Johannes, Gerber, Bernd, Hoffmann, Oliver, Park-Simon, Tjoung-Won, Reinisch, Mattea, Tio, Joke, Wimberger, Pauline, Boer, Katalin, Ballestrero, Alberto, Bianchini, Giampaolo, Biganzoli, Laura, Bordonaro, Roberto, Cognetti, Francesco, De Laurentiis, Michelino, De Placido, Sabino, Guarneri, Valentina, Montemurro, Filippo, Naso, Giuseppe, Santoro, Armando, Zamagni, Claudio, Kim, Seung-Jin, Nakamura, Seigo, Chae, Yee Soo, Cho, Eun Kyung, Hyun, Kim Jee, Im, Seock-Ah, Lee, Keun Seok, Park, Yeon Hee, Sohn, Joo Hyuk, Byrski, Tomasz, Huzarski, Tomasz, Kukielka-Budny, Bozena, Nowecki, Zbigniew, Szoszkiewicz, Renata, Tarnawski, Rafal, Dvornichenko, Viktoria, Moiseenko, Fedor, Mukhametshina, Guzel, Poddubskaya, Elena, Popova, Ekaterina, Tarasova, Anna, Vats, Anna, Adamo, Bárbara, Conejero, Raquel Andrés, Torres, Antonio Antón, Gelpi, Judith Balmaña, Fernández, Nieves Díaz, González, Alejandro Falcón, Garcia, Juan, Lorenzo-Lorenzo, Isabel, Antón, Fernando Moreno, Santisteban, Marta, Stradella, Agostina, Huang, Chiun-Sheng, Aksoy, Sercan, Arslan, Cagatay, Artac, Mehmet, Aydiner, Adnan, Ozyilkan, Ozgur, Sezer, Emel, Armstrong, Anne, Barrett, Sophie, Borley, Annabel, Kemp, Zoe, Michie, Caroline, Mukesh, Mukesh, Perren, Timothy, Swampillai, Angela, Young, Tammy
Published 2022